Metabolic activation of mifepristone [RU486; 17β-hydroxy-11 β-(4-dimethylaminophenyl)-17α-(1-propynyl)-estra-4,9-dien-3-one] by mammalian cytochromes p450 and the mechanism-based inactivation of human CYP2b6

Journal of Pharmacology and Experimental Therapeutics

Volumn 329, Issue 1, 2009, Pages 26-37

  Lin, Hsia Lien ^a   Zhang, Haoming ^a   Hollenberg, Paul F ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b 2301 MSRB III ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON; CYTOCHROME P450 2B6; DRUG METABOLITE; GLUTATHIONE; HEME; MIFEPRISTONE; OXYGEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ARTICLE; CHEMICAL BOND; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; COVALENT BOND; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME INACTIVATION; GLUTATHIONE METABOLISM; INCUBATION TIME; LIVER MICROSOME METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STOICHIOMETRY;

ANIMALS; APOPROTEINS; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRYSTALLIZATION; CYTOCHROME P-450 ENZYME SYSTEM; DEXAMETHASONE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME INDUCTION; GLUTATHIONE; HEME; HORMONE ANTAGONISTS; HUMANS; ISOENZYMES; MICROSOMES, LIVER; MIFEPRISTONE; NADP; OXIDOREDUCTASES, N-DEMETHYLATING; PHENOBARBITAL; RATS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SUBSTRATE SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 63849244585     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.148536     Document Type: Article

References (39)

1. Baillie TA and Davis MR (1993) Mass spectrometry in the analysis of glutathione conjugates. Biol Mass Spectrom 22:319-325.
2. Cadepond F, Ulmann A, and Baulieu EE (1997) RU486 (Mifepristone): mechanisms of action and clinical uses. Annu Rev Med 48:129-156.
3. CaJacob CA, Chan WK, Shephard E, and Ortiz de Montellano PR (1988) The catalytic site of rat hepatic lauric w-hydroxylase: protein versus prosthetic heme alkylation in the w-hydroxylation of acetylenic fatty acids. J Biol Chem 263: 18640-18649.
4. Chan WK, Sui Z, and Ortiz de Montellano PR (1993) Determinants of protein modification versus heme alkylation: inactivation of cytochrome P450 1A1 by 1-ethynylpyrene and phenylacetylene. Chem Res Toxicol 6:38-45.
5. Chasserot-Golaz S and Beck G (1992) How the potency of the steroid RU486 is related to P450 activities induced by dexamethasone and phenobarbital in rat hepatoma cells. J Steroid Biochem Mol Biol 41:653-657.
6. Chen Q, Doss GA, Tung EC, Liu W, Tang YS, Braun MP, Didolkar V, Strauss JR, Wang RW, Stearns RA, et al. (2006) Evidence for the bioactivation of zomepirac and tolmetin by an oxidative pathway: identification of glutathione adducts in vitro in human liver microsomes and in vivo in rats. Drug Metab Dispos 34:145-151.
7. Coon MJ, van der Hoeven TA, Dahl SB, and Haugen DA (1978) Two forms of liver microsomal cytochrome P450, P450 LM2 and P450 LM4 (rabbit liver). Methods Enzymol 52:109-117.
8. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, and Lindley CM (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222-1230.
9. Foroozesh M, Primrose G, Guo Z, Bell LC, Alworth WL, and Guengerich FP (1997) Aryl acetylenes as mechanism-based inhibitors of cytochrome P450-dependent monooxygenase enzymes. Chem Res Toxicol 10:91-102.
10. Gerber JG, Rhodes RJ, and Gal J (2004) Stereoselective metabolism of methadone N-demethylation by cytochrome P450 2B6 and 2C19. Chirality 16:36-44.
11. Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V, Martin H, Beaune P, and de Waziers I (1999) Human CPY2B6: expression, inducibility and catalytic activities. Pharmacogenetics 9:295-306.
12. Guengerich FP (1994) Analysis and characterization of enzymes, in Principles and Methods of Toxicology (Hayes AW ed), Raven Press, New York, pp 1259-1313.
13. Guengerich FP (2003) Cytochrome P450 oxidations in the generation of reactive electrophiles: epoxidation and related reactions. Arch Biochem Biophys 409:59-71.
14. He K, Woolf TF, and Hollenberg PF (1999) Mechanism-based inactivation of cytochrome P450 3A4 by mifepristone (RU486). J Pharmacol Exp Ther 288:791-797.
15. Heikinheimo O, Ylikorkala O, Turpeinen U, and Lahteenmaki P (1990) Pharmacokinetics of the antiprogesterone RU486: no correlation to clinical performance of RU486. Acta Endocrinol 123:298-304.
16. Helton ED, Williams MC, and Goldziecher JW (1977) Oxidative metabolism and de-ethynylation of 17α-ethynylestradiol by baboon liver microsomes. Steroids 30: 71-83.
17. Helvig C, Alayrac C, Mioskowski C, Koop D, Poullain D, Durst F, and Salaiin JP (1997) Suicide inactivation ofcytochrome P450 midchain and terminal acetylenes: a mechanistic study of inactivation of a plant lauric acid w-hydroxylase. J Biol Chem 272:414-421.
18. Huang Z, Roy P, and Waxman DJ (2000) Role of human microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide.Biochem Pharmacol 59:961-972.
19. Jang GR and Benet LZ (1998) Antiprogestin-mediated inactivation of cytochrome P450 3A4. Pharmacology 56:150-157.
20. Jang GR, Wrighton SA, and Benet LZ (1996) Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes. Biochem Pharmacol 52:753-761.
21. Khan KK, He YQ, Correia MA, and Halpert JR (2002) Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: selective inactivation of P450 3A4. Drug Metab Dispos 30:985-990.
22. Kent UM, Mills DE, Rajnarayanan RV, Alworth WL, and Hollenberg PF (2002) Effect of 17-α-ethynylestradiol on activities of cytochrome P450 2B (P4502B) enzymes: characterization of inactivation of P4560s 2B1 and 2B6 and identification of metabolites. J Pharmacol Exp Ther 300:549 -558.
23. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, and Zanger UM (2001) Extensive genetic polymorphism in human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399-415.
24. 5 dependent: metabolic activation of ethynyl moiety for the formation of glutathione, heme adducts and covalent binding to apoprotein. JPharmacol Exp Ther 321:276-287.
25. Lin HL, Kent UM, and Hollenberg PF (2005) The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5. J Pharmacol Exp Ther 313:154-164.
26. Lin HL, Myshkin E, Waskell L, and Hollenberg PF (2007) Peroxynitrite inactivation of human cytochrome P450s 2B6 and 2E1: heme modification and site-specific nitrotyrosine formation. Chem Res Toxicol 20:1612-1622.
27. Morris GM, Goodsell DS, Huey R, and Olson AJ (1996) Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. J Comput Aided Mol Des 10:293-304.
28. scc. J Biol Chem 258:6721-6723.
29. scc. J Steroid Biochem 36:273-280.
30. Ortiz de Montellano PR and Kunze KL (1980) Self-catalyzed inactivation of hepatic cytochrome P450 by ethynyl substrates. J Biol Chem 255:5578-5585.
31. Ortiz de Montellano PR and Kunze KL (1981) Shift ofthe acetylenic hydrogen during chemical and enzymatic oxidation of the biphenylacetylene triple bond. Arch Biochem Biophys 209:710-712.
32. Ortiz de Montellano PR and Komives EA(1985) Branchpoint for heme alkylation and metabolite formation in the oxidation ofarylacetylenes by cytochrome P450. J Biol Chem 260:3330 -3336.
33. 3-hydroxylase by mifepristone associated with loss of spectrally detectable cytochrome P450. Chem Biol Interact 118:39-49.
34. Scott EE, Spatzenegger M, and Halpert JR (2001) A truncation of 2B subfamily cytochromes P450 yields increased expression levels, increased solubility and decreased aggregation while retaining function. Arch Biochem Biophys 395:57-68.
35. Silverman RB (1996) Mechanism-based enzyme inactivation, in Contemporary Enzyme Kinetics and Mechanisms (Purich DL ed) pp 291-335, Academic Press, San Diego, CA.
36. Tang W and Miller RR (2004) Thiol conjugation in in vitro drug metabolism. in Methods in Pharmacology and Toxicology, Optimization in Drug Discovery: In vitro Methods (Yan Z and Cladwell GW eds) pp 369-383, Humana Press Inc., Totowa, NJ.
37. Teiber JF and Hollenberg PF (2000) Identification of the human liver microsomal P450s involved in the metabolism of N-nitrosodi-n-propylamine. Carcinogenesis 21:1559-1566.
38. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, and Desta Z (2003) The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306: 287-300.
39. Yukinaga H, Murayama N, Okzaki O, and Sudo K (2005) Structural analysis of covalent adducts to cytochrome P450 utilizing quadrupole time-of-flight mass spectrometry. Drug Metab Rev 37:158-159.